

Zhenhua Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5092576/publications.pdf>

Version: 2024-02-01

69
papers

1,853
citations

201674

27
h-index

302126

39
g-index

74
all docs

74
docs citations

74
times ranked

2315
citing authors

#	ARTICLE	IF	CITATIONS
1	The molecular mechanism of baicalein repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway. <i>Phytomedicine</i> , 2022, 100, 154046.	5.3	11
2	SPOCK1 promotes metastasis in pancreatic cancer via NF- κ B-dependent epithelial-mesenchymal transition by interacting with I κ B- β . <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 69-84.	4.4	11
3	miR-21-5p/Tiam1-mediated glycolysis reprogramming drives breast cancer progression via enhancing PFKL stabilization. <i>Carcinogenesis</i> , 2022, 43, 705-715.	2.8	4
4	Ezrin as a prognostic indicator regulates colon adenocarcinoma progression through glycolysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 710-720.	2.8	5
5	Lipid metabolism regulator human hydroxysteroid dehydrogenase-like 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4846-4859.	3.6	14
6	Commentary on statistical mechanical models of cancer. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2021, 572, 125877.	2.6	1
7	CD44 enhances adriamycin resistance in chronic myelogenous leukaemia cells K562. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 983-989.	1.3	0
8	The Significance of SIX1 as a Prognostic Biomarker for Survival Outcome in Various Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 622331.	2.8	1
9	SPOCK1/SIX1 axis promotes breast cancer progression by activating AKT/mTOR signaling. <i>Aging</i> , 2021, 13, 1032-1050.	3.1	10
10	Mortalin contributes to colorectal cancer by promoting proliferation and epithelial-mesenchymal transition. <i>IUBMB Life</i> , 2020, 72, 771-781.	3.4	19
11	Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer. <i>FEBS Journal</i> , 2020, 287, 2118-2133.	4.7	50
12	Significant association of PKM2 and NQO1 proteins with poor prognosis in breast cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153173.	2.3	10
13	Ezrin promotes hepatocellular carcinoma progression by modulating glycolytic reprogramming. <i>Cancer Science</i> , 2020, 111, 4061-4074.	3.9	15
14	Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 279-289.	2.5	13
15	Ezrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocation. <i>Cancer Management and Research</i> , 2019, Volume 11, 6553-6566.	1.9	29
16	Ectopic expression of HSDL2 is related to cell proliferation and prognosis in breast cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 6531-6542.	1.9	6
17	Paip1 overexpression is involved in the progression of gastric cancer and predicts shorter survival of diagnosed patients. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6565-6576.	2.0	11
18	The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming. <i>Cancer Letters</i> , 2019, 453, 170-183.	7.2	36

#	ARTICLE	IF	CITATIONS
19	<p>The prognostic value of Tiam1 correlates with its roles in epithelial–mesenchymal transition progression and angiogenesis in lung adenocarcinoma</p>. Cancer Management and Research, 2019, Volume 11, 1741-1752.	1.9	14
20	Ezrin promotes breast cancer progression by modulating AKT signals. British Journal of Cancer, 2019, 120, 703-713.	6.4	33
21	Role of Paip1 on angiogenesis and invasion in pancreatic cancer. Experimental Cell Research, 2019, 376, 198-209.	2.6	12
22	Mortalin is a distinct bio-marker and prognostic factor in serous ovarian carcinoma. Gene, 2019, 696, 63-71.	2.2	29
23	Paip1 predicts poor prognosis and promotes tumor progression through AKT/GSK-3 β pathway in lung adenocarcinoma. Human Pathology, 2019, 86, 233-242.	2.0	15
24	Paip1 Indicated Poor Prognosis in Cervical Cancer and Promoted Cervical Carcinogenesis. Cancer Research and Treatment, 2019, 51, 1653-1665.	3.0	11
25	Upregulation of Tiam1 contributes to cervical cancer disease progression and indicates poor survival outcome. Human Pathology, 2018, 75, 179-188.	2.0	11
26	Paip1 affects breast cancer cell growth and represents a novel prognostic biomarker. Human Pathology, 2018, 73, 33-40.	2.0	19
27	Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis. Gene, 2018, 647, 306-311.	2.2	42
28	Ezrin regulates skin fibroblast size/mechanical properties and YAP-dependent proliferation. Journal of Cell Communication and Signaling, 2018, 12, 549-560.	3.4	15
29	HBXIP over expression as an independent biomarker for cervical cancer. Experimental and Molecular Pathology, 2017, 102, 133-137.	2.1	20
30	DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Oncology Reports, 2017, 37, 857-864.	2.6	12
31	Mortalin expression in pancreatic cancer and its clinical and prognostic significance. Human Pathology, 2017, 64, 171-178.	2.0	20
32	Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncology Letters, 2017, 13, 2996-3002.	1.8	17
33	β -lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers. Scientific Reports, 2017, 7, 2681.	3.3	44
34	HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer. Journal of Ovarian Research, 2017, 10, 26.	3.0	16
35	DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer. Oncotarget, 2017, 8, 98708-98722.	1.8	33
36	Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC. Oncotarget, 2016, 7, 60169-60180.	1.8	34

#	ARTICLE	IF	CITATIONS
37	Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast. <i>BMC Cancer</i> , 2016, 16, 681.	2.6	21
38	Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma. <i>Oncology Letters</i> , 2016, 12, 3492-3498.	1.8	11
39	The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 42.	8.6	43
40	Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. <i>Oncotarget</i> , 2016, 7, 19631-19642.	1.8	36
41	NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. <i>BMC Cancer</i> , 2015, 15, 207.	2.6	76
42	High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. <i>BMC Cancer</i> , 2015, 15, 244.	2.6	56
43	Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. <i>Experimental and Molecular Pathology</i> , 2015, 98, 1-6.	2.1	39
44	LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 12893-900.	0.5	11
45	High Expression of Leucine Zipper-EF-Hand Containing Transmembrane Protein 1 Predicts Poor Prognosis in Head and Neck Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	9
46	Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 191.	2.6	29
47	Sineoculis homeobox homolog 1 protein is associated with breast cancer progression and survival outcome. <i>Experimental and Molecular Pathology</i> , 2014, 97, 247-252.	2.1	12
48	Clinical implications of high NQO1 expression in breast cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 14.	8.6	130
49	NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. <i>BMC Cancer</i> , 2014, 14, 414.	2.6	65
50	High expression of DEK predicts poor prognosis of gastric adenocarcinoma. <i>Diagnostic Pathology</i> , 2014, 9, 67.	2.0	34
51	Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma. <i>Experimental and Molecular Pathology</i> , 2014, 96, 54-60.	2.1	16
52	Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma. <i>Experimental and Molecular Pathology</i> , 2014, 96, 200-205.	2.1	42
53	Sineoculis homeobox homolog 1 protein as an independent biomarker for gastric adenocarcinoma. <i>Experimental and Molecular Pathology</i> , 2014, 97, 74-80.	2.1	12
54	Mechanisms Underlying Cancer Growth and Apoptosis by DEK Overexpression in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e111260.	2.5	20

#	ARTICLE	IF	CITATIONS
55	Overexpression of sineoculis homeobox homolog 1 predicts poor prognosis of hepatocellular carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 3018-27.	0.5	11
56	High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 5016-23.	0.5	15
57	DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2013, 13, 366.	2.6	55
58	High expression of ezrin predicts poor prognosis in uterine cervical cancer. <i>BMC Cancer</i> , 2013, 13, 520.	2.6	46
59	The Oncoprotein HBXIP Uses Two Pathways to Up-regulate S100A4 in Promotion of Growth and Migration of Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 30228-30239.	3.4	72
60	Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. <i>Diagnostic Pathology</i> , 2012, 7, 135.	2.0	42
61	DEK overexpression is correlated with the clinical features of breast cancer. <i>Pathology International</i> , 2012, 62, 176-181.	1.3	37
62	Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 49-54.	2.5	11
63	Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment. <i>Clinical Cancer Research</i> , 2009, 15, 570-577.	7.0	98
64	Clinicopathological significance of DEK overexpression in serous ovarian tumors. <i>Pathology International</i> , 2009, 59, 443-447.	1.3	34
65	Expression of Indian Hedgehog signaling molecules in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 235-240.	2.5	33
66	DEK overexpression in uterine cervical cancers. <i>Pathology International</i> , 2008, 58, 378-382.	1.3	42
67	Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. <i>Pathology International</i> , 2008, 58, 643-647.	1.3	12
68	^{125}I Np63 protein expression in uterine cervical and endometrial cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 811-816.	2.5	29
69	Cellular adjustment of gastric cancer for hepatic metastasis in successive orthotopic implantation model. <i>Cancer Biology and Therapy</i> , 2006, 5, 1313-1319.	3.4	7